Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fluzoparib in Platinum-Sensitive Ovarian Carcinoma: NCT07321015 Clinical Landscape Report 2026
18 September 2026
NCT07321015 clinical landscape for Platinum-Sensitive Ovarian Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Medroxyprogesterone Acetate in Endometrial Carcinoma: NCT07319429 Clinical Landscape Report 2026
18 September 2026
NCT07319429 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Metastatic Solid Tumor: NCT07318805 Clinical Landscape Report 2026
18 September 2026
NCT07318805 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Mucosal Melanoma: NCT07336979 Clinical Landscape Report 2026
18 September 2026
NCT07336979 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Avutometinib in Endometrial Carcinoma: NCT07318324 Clinical Landscape Report 2026
18 September 2026
NCT07318324 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abemaciclib in Triple Negative Breast Cancer: NCT07340541 Clinical Landscape Report 2026
18 September 2026
NCT07340541 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Multiple Myeloma: NCT07341867 Clinical Landscape Report 2026
18 September 2026
NCT07341867 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Melatonin in Endometrial Carcinoma: TCTR20260113003 Clinical Landscape Report 2026
18 September 2026
TCTR20260113003 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SL-28 in Pancreatic adenocarcinoma: NCT07341737 Clinical Landscape Report 2026
18 September 2026
NCT07341737 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Melanoma: NCT07340619 Clinical Landscape Report 2026
18 September 2026
NCT07340619 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
225Ac-TR2205 in Triple Negative Breast Cancer: NCT07340424 Clinical Landscape Report 2026
18 September 2026
NCT07340424 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Belimumab in Lupus Nephritis: NCT07340463 Clinical Landscape Report 2026
18 September 2026
NCT07340463 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.